| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/04/2009 | CA2706742A1 Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent |
| 06/04/2009 | CA2706656A1 Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
| 06/04/2009 | CA2706620A1 Conjugated beta-1,3-linked glucans |
| 06/04/2009 | CA2706578A1 Amino triazoles as pi3k inhibitors |
| 06/04/2009 | CA2706576A1 Pyridine compounds |
| 06/04/2009 | CA2706574A1 Aminothiazole derivatives |
| 06/04/2009 | CA2706565A1 Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester |
| 06/04/2009 | CA2706475A1 Phosphonic acid derivates and their use as p2y12 receptor antagonists |
| 06/04/2009 | CA2706448A1 Solvent systems for pour-on formulations for combating parasites |
| 06/04/2009 | CA2706432A1 Antiviral nucleoside compounds |
| 06/04/2009 | CA2706430A1 Polymorphs of a c-met/hgfr inhibitor |
| 06/04/2009 | CA2706381A1 Processes for preparing a substituted gamma-amino acid |
| 06/04/2009 | CA2706379A1 A method for producing adapalene gels |
| 06/04/2009 | CA2706333A1 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the .beta.2 adrenergic receptor |
| 06/04/2009 | CA2706171A1 Fused indane compound |
| 06/04/2009 | CA2706018A1 1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders |
| 06/04/2009 | CA2705906A1 Imidazo-thiazole derivatives as protein kinase inhibitors |
| 06/04/2009 | CA2705583A1 Derivatives of 6,7-dihydro-5h-imidazo[1,2-.alpha.]imidazole-3-carboxylic acid amides |
| 06/04/2009 | CA2705408A1 New therapeutic approaches for treating cmt and related disorders |
| 06/04/2009 | CA2705262A1 Angiotensin ii receptor antagonists |
| 06/04/2009 | CA2704826A1 Method for producing granulated preparation |
| 06/04/2009 | CA2704493A1 Organic compounds |
| 06/04/2009 | CA2703913A1 Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate |
| 06/04/2009 | CA2703561A1 Novel polymorphic form of rotigotine and process for production |
| 06/04/2009 | CA2702437A1 Method of delaying the onset of clinically definite multiple sclerosis |
| 06/04/2009 | CA2701516A1 C2-c5-alkyl-imidazole-bisphosphonates |
| 06/04/2009 | CA2699590A1 Use of purine derivatives for the manufacture of a medicament |
| 06/04/2009 | CA2694572A1 Drug for alleviating motor complications or psychiatric symptoms of parkinson's disease |
| 06/04/2009 | CA2670341A1 Vigor enhancement via administration of pyrimidine derivatives |
| 06/03/2009 | EP2065468A1 Modifications of hiv env enhance immunogenicity for genetic immunization |
| 06/03/2009 | EP2065401A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 06/03/2009 | EP2065400A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 06/03/2009 | EP2065388A1 Pyrazolopyrimidine derivative |
| 06/03/2009 | EP2065386A1 CGRP antagonists |
| 06/03/2009 | EP2065385A1 Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester |
| 06/03/2009 | EP2065384A1 Tricyclic thrombin receptor antagonist |
| 06/03/2009 | EP2065383A1 Indazole compounds and methods of use thereof as protein kinase inhibitors |
| 06/03/2009 | EP2065382A1 CGRP antagonists |
| 06/03/2009 | EP2065381A1 CGRP antagonists |
| 06/03/2009 | EP2065380A1 Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
| 06/03/2009 | EP2065379A1 Benzimidazole compound having gastric acid secretion inhibitory activity |
| 06/03/2009 | EP2065377A1 Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same |
| 06/03/2009 | EP2065375A1 A process for the preparation of 7-carboxymethyloxy-3',4', 5-trimethoxy flavone |
| 06/03/2009 | EP2065372A1 Antitumor agent for undifferentiated gastric cancer |
| 06/03/2009 | EP2065369A1 Urea compound or salt thereof |
| 06/03/2009 | EP2065368A1 Inhibitors of IAP |
| 06/03/2009 | EP2065366A2 HIF hydroxylase inhibitors |
| 06/03/2009 | EP2065358A1 The prepartion and the use of ethoxy combretastatins and their prodrugs |
| 06/03/2009 | EP2065056A1 Hydrophilic matrix having poorly water-soluble compound sealed therein, and method for producing the same |
| 06/03/2009 | EP2065053A1 Cell death inhibitor |
| 06/03/2009 | EP2065051A2 Composition for maintaining gastrointestinal homeostasis comprising albumin and tannic acid |
| 06/03/2009 | EP2065047A1 Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| 06/03/2009 | EP2065046A1 Gip secretion inhibitor |
| 06/03/2009 | EP2065045A1 Antioxidant for preventing and treating diseases caused by oxidative stress |
| 06/03/2009 | EP2065044A1 Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| 06/03/2009 | EP2065043A1 Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent |
| 06/03/2009 | EP2065042A2 Antiparasitic composition containing an organic amine salt of closantel |
| 06/03/2009 | EP2065041A1 Use of medium chain triglycerides for the treatment and prevention of Parkinson's disease, Huntington' disease or Amyloid Lateral Sclerosis resulting from reduced neuronal metabolism |
| 06/03/2009 | EP2065040A2 Sphingolipids against pathological processes in lipid rafts |
| 06/03/2009 | EP2065039A1 Selective inhibition of Polo-like kinase 1 |
| 06/03/2009 | EP2065038A1 New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| 06/03/2009 | EP2065037A1 Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (Tlx) |
| 06/03/2009 | EP2065036A1 Vitamin supplement |
| 06/03/2009 | EP2065035A1 Pharmaceutical formulations containing irbesartan |
| 06/03/2009 | EP2065034A2 Enteric-coated glucosinolates and beta-thioglucosidases |
| 06/03/2009 | EP2065033A1 Microemulsions of cannabinoid receptor binding compounds |
| 06/03/2009 | EP2065032A1 A method for producing adapalene gels |
| 06/03/2009 | EP2064951A1 Use of a substituted imidazole, derivatives or salts thereof for the preparation of a medicament for the treatment of a cell proliferative disorder |
| 06/03/2009 | EP2064556A2 Method to identify and treat subjects resistant to acetyl salicylic acid |
| 06/03/2009 | EP2064328A2 Sensitization of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions |
| 06/03/2009 | EP2064252A2 Process for the preparation of sevelamer hydrochloride and formulation thereof |
| 06/03/2009 | EP2064235A1 The death receptor cd95 controls neurogenesis of adult neural stem cells in vivo and in vitro |
| 06/03/2009 | EP2064227A2 Processes for the preparation of ciclesonide and its crystal form |
| 06/03/2009 | EP2064216A2 Crystal form of epothilone b and use in pharmaceutical compositions |
| 06/03/2009 | EP2064215A1 Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof |
| 06/03/2009 | EP2064214A1 Pyraz0l0(l,5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors |
| 06/03/2009 | EP2064213A1 Heteroaryl derivatives as protein kinase inhibitors |
| 06/03/2009 | EP2064212A1 Pyrrolo isoquinolines as kinase inhibitors |
| 06/03/2009 | EP2064211A1 IMIDAZO[1,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE |
| 06/03/2009 | EP2064210A1 Polymorph of (r) -3- (2-hydroxy-2, 2-diphenyl-acetoxy) -1- (isoxazol-s-ylcarbamoyl-methyl) -1-azoni a-bicyclo- [2.2.2] octane bromide |
| 06/03/2009 | EP2064209A1 Pyrrole derivatives with antibacterial activity |
| 06/03/2009 | EP2064208A1 Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function |
| 06/03/2009 | EP2064207A2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 06/03/2009 | EP2064206A2 Crystalline forms of tiagabine hydrochloride and processes for the preparation of amorphous tiagabine hydrochloride |
| 06/03/2009 | EP2064204A1 Inhibitors of 5 -lipoxygenase activating protein ( flap) |
| 06/03/2009 | EP2064203A1 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| 06/03/2009 | EP2064202A2 A new crystalline form g of (5s)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonyl-methyl]-5-methyl-imidazolidine-2,4-dione (i) and intermediates thereof. |
| 06/03/2009 | EP2064200A1 Derivatives of 2-phenyl-3-hydroxyquinoline-4(1h)-one and methods of their preparation and utilization |
| 06/03/2009 | EP2064199A1 Diaryl ether derivatives and uses thereof |
| 06/03/2009 | EP2064198A2 Substituted indanyl sulfonamide compounds, their preparation and use as medicaments |
| 06/03/2009 | EP2064197A2 3,4-dihydrobenzo[1,2,3]thiadiazine-1,1-dioxide derivatives, process for preparation thereof, medicaments containing said derivatives and their use |
| 06/03/2009 | EP2064195A2 Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and pharmaceutical formulations thereof |
| 06/03/2009 | EP2064194A2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 06/03/2009 | EP2064193A1 Heterocyclic gpr40 modulators |
| 06/03/2009 | EP2064191A1 Aspartyl protease inhibitors |
| 06/03/2009 | EP2064189A2 Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one |
| 06/03/2009 | EP2064188A1 Fungicidal pyridazines, method for the production thereof, and use thereof for controlling fungi and agents containing the same |
| 06/03/2009 | EP2064186A1 Azabicyclic compounds as inhibitors of monoamines reuptake |
| 06/03/2009 | EP2064185A1 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions |
| 06/03/2009 | EP2064184A1 Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |